KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Assets (2016 - 2025)

Historic Current Assets for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $97.4 million.

  • Arbutus Biopharma's Current Assets fell 2661.23% to $97.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.4 million, marking a year-over-year decrease of 2661.23%. This contributed to the annual value of $127.3 million for FY2024, which is 356.82% down from last year.
  • Per Arbutus Biopharma's latest filing, its Current Assets stood at $97.4 million for Q3 2025, which was down 2661.23% from $103.1 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Current Assets ranged from a high of $172.7 million in Q1 2022 and a low of $83.5 million during Q2 2021
  • Over the past 5 years, Arbutus Biopharma's median Current Assets value was $137.3 million (recorded in 2021), while the average stood at $135.7 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 8904.82% in 2022, then plummeted by 3042.84% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Current Assets (Quarter) stood at $160.7 million in 2021, then dropped by 5.93% to $151.1 million in 2022, then dropped by 12.65% to $132.0 million in 2023, then decreased by 3.57% to $127.3 million in 2024, then dropped by 23.46% to $97.4 million in 2025.
  • Its Current Assets was $97.4 million in Q3 2025, compared to $103.1 million in Q2 2025 and $116.8 million in Q1 2025.